TALKWIRE LIMITED

Financial Health Assessment: TALKWIRE LIMITED

1. Financial Health Score: C+

Explanation: While the company has a long history of stability and retains a positive net asset position, the most recent financial period reveals a severe acute condition. The sudden and dramatic loss of over £1.2 million in equity over a short four-month period, coupled with a significant drop in cash and debtors, indicates a major recent financial trauma—likely a substantial bad debt write-off or severe trading loss. The patient is stable but requires immediate critical care to prevent further deterioration.

2. Key Vital Signs

• Net Assets (The Patient's Weight/Body Mass): Dropped drastically from £1,954,903 (Nov 2024) to £680,007 (Mar 2025). This represents a 65% loss of body mass in just four months. While the patient is still "alive" (solvent), this level of rapid weight loss is a severe symptom of distress.
• Cash Position (Blood Flow): Cash at bank fell from £1,001,271 to £584,388. While cash reserves are still adequate to meet immediate needs, the bleeding is significant. The company has moved from a position of high liquidity to a more standard, but still healthy, cash cover.
• Debtors (The Digestive System): Debtors dropped from £1,573,146 to £864,175. While a reduction in debtors can sometimes mean improved collections, the simultaneous drop in retained earnings strongly suggests that a large portion of this reduction is due to a bad debt write-off. The company has essentially "vomited" up revenue it thought it had digested.
• Current Liabilities (Cholesterol/Blockages): Amounts falling due within one year increased from £878,121 to £1,025,810. The pressure on the company's short-term obligations is increasing, even as its current assets shrink.
• Current Ratio (Blood Pressure): Previously a very healthy 2.99x (Nov 2024), this has dropped to 1.46x (Mar 2025). This is still within normal limits (above 1.0x), meaning the company can pay its short-term debts, but the sudden drop in "blood pressure" is concerning.

3. Diagnosis

Diagnosis: Acute Financial Shock secondary to probable significant impairment.

The longitudinal view shows a patient that was in robust health for years, growing steadily from 2016 to 2024. Net assets grew from £569k to nearly £2 million, and cash peaked at £1.7 million in 2022.

However, the latest filing covers a shortened period (1 Dec 2024 to 31 Mar 2025). During this brief window, the company suffered a catastrophic hit to its retained earnings, which fell by £1,274,896.

Given that the reduction in debtors (£708,971 drop) accounts for a significant portion of the asset reduction, the most likely diagnosis is that the company suffered a major bad debt or impairment that it was forced to write off, eroding its accumulated profits severely. The company is not insolvent—it still has positive net assets and adequate cash—but its financial immune system has been heavily compromised, and its reserves have been depleted.

4. Recommendations

1. Stop the Bleeding (Urgent Investigation): Management must immediately diagnose the root cause of the £1.2m equity drop. If it was a bad debt, credit control procedures must be reviewed. If it was a trading loss, the underlying business model needs urgent restructuring.
2. Blood Transfusion (Cash Preservation): With cash dropping by over 40% in a few months, the company must prioritize cash flow. Delay non-essential capital expenditure and focus on accelerating debtor collection to ensure liquidity remains stable.
3. Monitor Vital Signs Closely: The shift to a shorter reporting period is unusual and may signal a change in the business (such as a sale or restructuring). Stakeholders should monitor the next full-year accounts closely to see if this was a one-off event or the start of a chronic condition.
4. Review Creditor Terms: With current liabilities rising, the company should ensure it is not stretching its suppliers, which could lead to a loss of credit terms and further "blockages" in the supply chain.